Real‐World Outcomes With Low‐Dose Dasatinib (50 mg) in Imatinib‐Resistant Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Analysis of Efficacy and Safety
Low-dose dasatinib is effective and tolerable in imatinib-resistant CML-CP, with nearly two-thirds achieving DMRs. Predictive biomarkers (T315I mutation, high ELTS risk, high baseline BCR-ABL1) can guide dose optimization.
Authors
- Souvik Saha (ORCID: https://orcid.org/0000-0002-7971-9776)
- Mona Vijayaran
- Harshal Mamlekar (ORCID: https://orcid.org/0009-0001-5007-8602)
- Manish Kumar Singh (ORCID: https://orcid.org/0000-0002-6844-6899)
- SK Yadav
- Rajesh Kashyap
- Nandhini Gangadaran
- Ruchi Gupta
- Khaliqur Rahman
- Dinesh Chandra
Institutions
- Sanjay Gandhi Post Graduate Institute of Medical Sciences (IN)
Publication Details
- Journal
- Cancer Reports
- Published
- 2026-01-01
- DOI
- https://doi.org/10.1002/cnr2.70400
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00